Important pharmacy news and late-breaking industry information updated daily.
FDA on Monday approved the sickle cell disease drug voxelotor (Oxbryta—Global Blood Therapeutics), adding to a new wave of treatments that promise relief from the life-threatening blood disorder that largely afflicts African-Americans.
Cynthia Knapp Dlugosz, BSPharm, NBC-HWC, has been immersed in the mindfulness community for more than 20 years, learning from some of the world’s leading mindfulness experts. Lately, her two paths—mindfulness and pharmacy—have become intertwined.
Amid a multistate outbreak of E. coli, CDC on Friday warned consumers not to eat any type of romaine lettuce harvested from Salinas, CA. According to the agency, 40 people have been infected with the outbreak strain of E. coli 0157:H7 in 16 states.
FDA is taking measures to prevent the abuse and misuse of loperamide, the antidiarrheal medication that is available without a prescription. The agency announced that it is working with manufacturers to limit the number of doses in a package.
According to updated recommendations from CDC’s Advisory Committee on Immunization Practices (ACIP), shared clinical decision making is recommended for PCV13 vaccination consideration in persons aged 65 years and older who do not have an immunocompromising condition, cerebrospinal fluid leak, or cochlear implant and who have not previously received PCV13.
FDA on Thursday approved cenobamate tablets (XCOPRI—SK Life Science) to treat partial-onset seizures in adults.
FDA on Wednesday approved givosiran (Givlaari—Alnylam Pharmaceuticals) for the treatment of adults with acute hepatic porphyria. The rare genetic disorder causes the buildup of toxic porphyrin molecules, which are formed during the production of heme.
CDC on Tuesday released updated guidance for health care providers to help diagnose and treat patients with e-cigarette or vaping lung injury (EVALI).
Results from the international ISCHEMIA trial, the largest study to address the effect of opening blocked arteries in nonemergency situations, showed that patients who had invasive procedures to prevent cardiovascular events did no better than patients who received drug therapy treatment. The trial results were presented at the annual meeting of the American Heart Association over the weekend.
Members of Congress on Monday harshly criticized President Trump’s decision to hold off on a possible ban of flavored e-cigarette. Rep.